Affiliation:
1. Saint Luka Lugansk State Medical University, Ministry of Health of the Russian Federation
Abstract
Aim. To investigate pharmacokinetic and pharmacodynamic interactions of levofloxacin, kanamycin and linezolid in combined chemotherapy of multidrug-resistant tuberculosis.Materials and Methods. We investigated pharmacological interactions between levofloxacin, kanamycin and linezolid using GalaxyWEB GalaxySagittarius – AlphaFold software.Results. We found that levofloxacin can interact through the carboxyl group (–COOH) with compounds containing an amino group, in particular with linezolid and kanamycin, in order to form a carbamide bond -CO-NH-. Levofloxacin is also able to form an azomethine bond via the carbonyl group –C = O with drugs containing the primary amino group (kanamycin and linezolid). 3D models of the drug compounds with plasma proteins were visualized and protein matches of paired intake of drugs were determined: Levofloxacin – Linezolid pair – 181 matches, Levofloxacin – Kanamycin pair – 11 matches, Kanamycin – Linezolid pair – 8 matches. After 1.5-2 hours after the intake of levofloxacin – linezolid - kanamycin, these drugs reached peak concentrations. Levofloxacin and linezolid were primarily metabolized in the liver and kanamycin has not been metabolized at all. All three drugs were excreted by the kidneys.Conclusion. The analysis demonstrated effectiveness of Galaxy Sagittarius – AlphaFold technology and found a significant level of drug-protein complexes. The interaction of linezolid, levofloxacin and kanamycin led to an increase in the effectiveness and safety of pharmacotherapy, underlying their rational combination.
Publisher
Kemerovo State Medical University
Reference23 articles.
1. Mozhokina G.N., Samoilova A.G., Vasilyeva I.A. Beta-lactam antibiotics as reserve medications for the treatment of drug-resistant tuberculosis. Antibiot i Khimioter = Antibiotics and Chemotherapy. 2021;66(5-6):78-85. (in Russ). https://doi.org/10.24411/0235-2990-2021-66-5-6-78-85
2. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022. Geneva: World Health Organization; 2022. Available at : https://www.who.int/publications/i/item/9789240018662. Accessed: February 23, 2022.
3. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, 27-29 October 2020. Geneva: World Health Organization; 2021. Available at : https://www.who.int/publications/i/item/9789240018662. Accessed: February 23, 2022.
4. Wallis RS, Maeurer M, Mwaba P, Chakaya J, Rustomjee R, Migliori GB. Tuberculosis – advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect Dis. 2016;16:34-46. https://doi.org/10.1016/S1473-3099(16)00070-0
5. Ruzanov DY, Skriagina AM, Buinevich IV, Goponiako SV, Balasaniantc GS, Khimova ES. New regimens and new medications in the treatment of tuberculosis: keeping step? New schemes and new drugs in the treatment of tuberculosis: are we keeping up? Clinical microbiology and antimicrobial chemotherapy. 2021;23(1):27-42. (in Russ). https://doi.org/10.36488/cmac.2021.1.27-425